2010
Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: A randomized trial
Toll BA, White M, Wu R, Meandzija B, Jatlow P, Makuch R, O’Malley S. Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: A randomized trial. Drug And Alcohol Dependence 2010, 111: 200-206. PMID: 20542391, PMCID: PMC3771701, DOI: 10.1016/j.drugalcdep.2010.04.015.Peer-Reviewed Original ResearchConceptsWeight gainSmoking cessationPoint prevalence smoking abstinence ratePre-specified primary outcomesLow-dose naltrexoneOpen-label therapySmoking abstinence ratesPoint prevalence abstinenceReduced weight gainNaltrexone augmentationPlacebo groupNicotine replacementPrimary outcomeQuit dateAbstinence ratesLabel therapyNicotine patchBehavioral counselingNaltrexoneAbstinent participantsSmokersWeight concernsWeeksCessationLower rates
1994
Low-dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial.
Ment L, Ehrenkranz R, Duncan C, Scott D, Taylor K, Katz K, Schneider K, Makuch R, Oh W, Vohr B, Philip A, Allan W. Low-dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial. Pediatrics 1994, 93: 543-50. PMID: 8134206, DOI: 10.1542/peds.93.4.543.Peer-Reviewed Original ResearchConceptsLow birth weight neonatesSeverity of IVHBirth weight neonatesIntraventricular hemorrhageWeight neonatesDose indomethacinBirth weightGrade 4 intraventricular hemorrhageSerial cranial ultrasound examinationsSignificant adverse drug eventsPercent of neonatesPlacebo-controlled trialPatent ductus arteriosusCranial ultrasound examinationMajor risk factorAdverse drug eventsHours of ageFirst postnatal dayDuctal closureProphylactic indomethacinApgar scoreNeurodevelopmental handicapParenchymal involvementPlacebo groupAdverse events
1990
A multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. The Ribavirin-LAS Collaborative Group.
Roberts R, Dickinson G, Heseltine P, Leedom J, Mansell P, Rodriguez S, Johnson K, Lubina J, Makuch R. A multicenter clinical trial of oral ribavirin in HIV-infected patients with lymphadenopathy. The Ribavirin-LAS Collaborative Group. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1990, 3: 884-92. PMID: 1974628.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdministration, OralAdolescentAdultCD4 AntigensCD4-Positive T-LymphocytesDose-Response Relationship, DrugDouble-Blind MethodEvaluation Studies as TopicHumansImmunoblastic LymphadenopathyLeukocyte CountMaleMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicRibavirinRibonucleosidesConceptsOral ribavirinActive treatmentBaseline CD4 cell countMajor protocol violationsCD4 cell countPlacebo-controlled trialMulticenter clinical trialSignificant differencesPlacebo patientsPlacebo groupPlacebo treatmentStudy entryTreat analysisWashout periodDaily dosesClinical trialsKaposi's sarcomaProtocol violationsMedical CenterTreatment superiorityTreatment groupsPlaceboRibavirinPatientsOverall significant difference